Account
Watchlists
Bookmarks
Pricing
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Bearish
3
Neutral
8
Bullish
3
Bearish
19
Neutral
16
Bullish
11
Bearish
16
Neutral
8
Bullish
8
Market Cap
₹ 168 Cr
P/E
31.43
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
66.05 | 187 Cr | 52.39 | 1.29 | 0.00 | 2.41 | 5.22 | 1.22 | |
132.95 | 172 Cr | 13.97 | 1.24 | 0.61 | 8.89 | 11.28 | 7.20 | |
160.00 | 168 Cr | 31.43 | 3.00 | 0.00 | 8.67 | 10.26 | 3.81 | |
260.00 | 161 Cr | 87.81 | 3.76 | 0.00 | 4.47 | 7.31 | 1.55 | |
32.78 | 155 Cr | 18.88 | 13.34 | 0.00 | 70.62 | 33.57 | 8.06 | |
70.00 | 151 Cr | — | 0.00 | 0.00 | 17.42 | -19.17 | -16.35 | |
115.20 | 145 Cr | 32.09 | 2.32 | 0.00 | 7.24 | 10.49 | 3.28 |
Astonea Labs Ltd is focused on manufacturing and marketing pharmaceutical and cosmetic products, including antibiotics and multivitamins, used for skin, hair, and tooth care.
The company also operates as a contract manufacturer for both domestic and international firms, highlighting its expansive operational reach.
In recent strategic moves, Astonea Labs announced plans for a public issue of 27,90,000 Equity Shares, signaling potential growth and expansion.
Astonea Labs markets its own products in India under the brands 'Glow Up' and 'Regero', showcasing its diversified product portfolio.
The company has steadily expanded its production capabilities since 2019, indicating robust growth in its manufacturing operations.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs
168 Cr
Low Risk
31.4
59.2
0.2
3.0
185.00
118.00
Sales CAGR
1Y
21.61%
3Y
48.04%
5Y
—
10Y
—
Profit CAGR
1Y
31.45%
3Y
178.09%
5Y
—
10Y
—
ROE
TTM
8.67%
3Y
26.25%
5Y
—
10Y
—
ROCE
TTM
10.26%
3Y
22.34%
5Y
—
10Y
—
Performance
STEADY PERFORMER
Valuation
REASONABLE
Growth
EXCEPTIONAL
Profitability
MODERATE MARGIN
Technicals
Bearish
Risk
LOW RISK
